Ascentage Pharma Group International (AAPG)

CIK 0002023311 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Cover
—
Audit Information
—
Statements
Consolidated Statements of Profit Or Loss
—
Consolidated Statements of Comprehensive Loss
—
Consolidated Statements of Financial Position
—
Consolidated Statements of Financial Position (P)
—
Consolidated Statements of Changes In Equity
—
Consolidated Statements of Cash Flows
—
Notes
Accounting Policies
—
Approval of The Financial Statements
—
Cash and Bank Balances
—
Commitments
—
Condensed Financial Information of The Company
—
Contingent Liabilities
—
Contract Liabilities
—
Corporate and Group Information
—
Cybersecurity Risk Management and Strategy Disclosure
—
Deferred Income
—
Deferred Tax
—
Dividends
—
Event After The Reporting Period
—
Fair Value and Fair Value Hierarchy of Financial Instruments
—
Finance Costs
—
Financial Assets At Fair Value Through Profit Or Loss
—
Financial Instruments By Category
—
Financial Risk Management Objectives and Policies
—
Goodwill
—
Income Tax
—
Insider Trading Policies and Procedures
—
Interest-bearing Bank and Other Borrowings
—
Inventories
—
Investment In A Joint Venture
—
Investment Property
—
Leases
—
Long-term Payables
—
Loss Before Tax
—
Loss Per Share Attributable To Ordinary Equity Holders of The Company
—
Notes To The Consolidated Statements of Cash Flows
—
Operating Segment Information
—
Other Expenses
—
Other Intangible Asset
—
Other Non-current Assets
—
Other Payables and Accruals
—
Pledge of Assets
—
Prepayments, Other Receivables and Other Assets
—
Property, Plant and Equipment
—
Related Party Transactions
—
Reserves
—
Revenue, Other Income and Gains
—
Share Capital and Treasury Shares
—
Share-based Payments
—
Significant Accounting Judgements and Estimates
—
Trade Payables
—
Trade Receivables, Net
—